Functional Diagnostics in California

Echolight S.p.A. is an Italian medical device manufacturer specializing in bone density assessment and osteoporosis diagnosis. The company originated as a spin-off from Italy's Consiglio Nazionale delle Ricerche (CNR) and markets the EchoS system—a non-ionizing radiation bone densitometer that uses proprietary Radiofrequency Echographic Multi Spectrometry (R.E.M.S.) technology. The EchoS device performs ultrasound-based scanning of the lumbar spine and proximal femur to evaluate bone mineral density (BMD), T-score, Z-score, and bone microarchitecture quality without exposing patients to ionizing radiation. Scan time is rapid: 80 seconds for spine assessment, 40 seconds for femur. The system produces immediate medical reports with fracture risk indices and body composition data. Key clinical advantages over dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) include radiation-free operation, portability, lack of need for certified operators or shielded rooms, and applicability to pediatric, pregnant, diabetic, oncology, and secondary osteoporosis patients. EchoS is available in both stationary and portable configurations. The company holds FDA clearance, CE marking, ISO 13485:2016 quality management certification, ISO 9001:2015 compliance, and multiple international regulatory approvals. Echolight's R.E.M.S. technology is recognized in Italian Ministry of Health clinical guidelines (ISS guidelines on fragility fracture diagnosis and risk stratification). The company engages in ongoing clinical validation at major international osteoporosis centers and participates in scientific symposia including WCO-IOF-ESCEO conferences.

Mindera Health develops precision medicine diagnostics for dermatological conditions, specifically psoriasis. The company's flagship product, Mind.Px™, is a non-invasive diagnostic patch that captures thousands of RNA transcripts from a penny-sized skin sample in approximately five minutes. The device employs Dermal Intelligence™ technology to enable scalable collection and analysis of individualized genetic information, providing actionable, data-driven treatment guidance for patients, providers, and payers. Mind.Px is designed to support biologic therapy selection for psoriasis patients, reducing trial-and-error treatment approaches. The company markets directly to healthcare providers and patients, offering physician resources, online test ordering, and patient education materials. Mindera Health has received regulatory approval from the New York State Department of Health as of April 2026, enabling national availability across all 50 states. The platform combines genomic RNA analysis with clinical dermatology to support precision treatment decisions. Target users include dermatologists, rheumatologists, and other providers managing psoriasis patients seeking to optimize biologic therapy outcomes.

Darmiyan, Inc. is a neuroscience-driven AI and medical imaging software company developing diagnostic tools for early detection and monitoring of neurodegenerative diseases, specifically Alzheimer's disease and dementia. The company's core technology leverages over four decades of pioneering brain research combined with advanced machine learning and medical image processing to analyze cellular-level changes in brain MRI scans. BrainSee, Darmiyan's flagship FDA De Novo-approved software, utilizes proprietary algorithms to quantify microscopic tissue architecture changes (voxel-level analysis) within standard clinical-grade MRI scans, enabling non-invasive early disease detection and patient-specific monitoring of therapeutic responses. The company targets three primary markets: early Alzheimer's detection in at-risk populations, objective measurement of patient response to interventions, and biomarker development for pharmaceutical drug development programs. Darmiyan's technology is designed around four core pillars: high diagnostic accuracy, non-invasiveness, seamless integration with existing MRI infrastructure, and global accessibility. The platform operates without requiring specialized imaging hardware, positioning it for broad adoption across healthcare settings. FDA Breakthrough Designation was granted to BrainSee for its potential to improve treatment of Alzheimer's disease. Third-party clinical validation has been completed in the US and Canada by independent research investigators. The company serves healthcare providers, pharmaceutical development teams, academic medical centers, and clinical research organizations pursuing precision brain health screening and monitoring solutions.

Phase Scientific International Limited develops proprietary diagnostic technology and rapid testing solutions for early disease detection, with focus on cancer and infectious diseases. The company's core innovation is PHASIFY™, a molecular detection platform that enables faster, easier identification of target biomarkers compared to conventional diagnostics. PHASIFY™ powers three product and service lines: INDICAID® at-home rapid tests for point-of-care use; INDICAID lab™ at-home laboratory testing kits; and PHASE lab, a clinical laboratory service offering cancer and infectious disease testing. Recent product launches include FebriDx®, a respiratory pathogen test awarded FDA CLIA waiver (March 2026), and urine-based HPV screening for cervical cancer detection. The company markets solutions for cancer screening, cervical health monitoring, and respiratory/infectious disease diagnostics. Manufacturing and regulatory capabilities include FDA CLIA certification and active clinical research partnerships. The company has raised $34 million Series A funding and maintains operations in Asia and North America, positioning itself as an innovator in preventive diagnostics and non-invasive biomarker detection.

Medi/Nuclear Corporation is a manufacturer and distributor of specialized lung imaging systems for nuclear medicine. Since 1973, the company has focused exclusively on radioaerosol and xenon delivery systems for ventilation lung scans, serving nuclear technicians, radiologists, and physicians. Their proprietary systems employ advanced nebulizer technology producing fine and ultra-fine particles for superior alveolar deposition and image quality in both SPECT and planar imaging modalities. The company's product lines include the Aero/Vent and Insta/Vent radioaerosol delivery systems with unidirectional airflow design, HEPA filtration, and multiple delivery options (mouthpiece shields, face masks, ventilator-compatible kits). All systems emphasize safety with enhanced radioactive contamination and infection control features, supported by comprehensive training materials and appropriate use criteria documentation.

MEDTOX Diagnostics, Inc. is a point-of-care diagnostic company specializing in rapid immunoassay-based drug screening devices. The company manufactures rapid test cassettes, screening cups, and automated readers for substance abuse testing across clinical, workplace, criminal justice, and hospital settings. Primary product lines include MEDTOX PROFILE® cassettes and MEDTOX EZ-SCREEN® cups for screening up to 11 drugs of abuse with results in minutes, and the MEDTOX Scan® automated reader system for high-throughput, convenient screening. The company also offers a fentanyl test device recently cleared by FDA. MEDTOX serves hospitals, workplace wellness programs, clinical trial sponsors, and criminal justice agencies. As of 2026, the company is transitioning its trade name to Labcorp Point of Care under parent company Labcorp ownership. Products are designed for rapid point-of-care screening and typically achieve results within minutes of sample collection. The company provides training and customer support resources for clinical and administrative users.

Logos Systems International manufactures digital camera-based quality assurance phantoms for proton therapy and X-ray beam systems used in radiation oncology. The company specializes in 3D and 2D beam phantoms that perform end-to-end measurements with superior precision and speed, replacing traditional film-based measurement approaches. Product lines include the XRV-3000 Eagle and XRV-4000 Hawk beam profiler phantoms with modular accessories such as the LCW-300 stepped wedge and Proton Beam Range Verification modules for imaging Bragg peaks in proton and heavy ion beams. The company also provides BeamWorks client-server software for data analysis and quality assurance workflows. Applications encompass linac and proton beam QA, FLASH radiotherapy, proton arc therapy, and isocenter analysis (Starshot methodology). Target customers include radiation oncology departments, treatment centers, and medical physics programs requiring regulatory compliance and precision dosimetry verification. Products support real-time 3D beam vector and profile capture across 360-degree rotations and integrate high-energy radiation detection with precision two-dimensional metrology for comprehensive beam characterization.

BioCheck, Inc. is a leader in value-based diagnostics and data monetization, offering high-quality in vitro diagnostic immunoassay devices. The company manufactures and distributes a comprehensive range of diagnostic products including instruments, antibodies, and ELISA kits designed for clinical and research applications. Following the August 2021 acquisition of DRG International, BioCheck operates a global network with subsidiaries and offices across the USA, Germany, Russia, Poland, and Czech Republic, providing distribution capacity to customers in over 110 countries. The DRG:HYBRiD-XL® is a fully automated analyzer for immunoassays and clinical chemistry. Product lines span diagnostic ELISAs, chemiluminescent assays, and specialized antibodies for applications including diabetes diagnosis, endocrinology, prenatal/neonatal supervision, and thyroid function testing. BioCheck emphasizes value-based diagnostics—delivering cost-effective, evidence-based diagnostic testing to improve patient outcomes and reduce unnecessary testing—alongside healthcare data monetization and shared savings models. The company aligns with well-established diagnostic principles, focusing on accessible, reliable tools for hospitals, clinics, research laboratories, and resource-limited settings.

Aptitude Medical Systems is a deep-tech healthcare company specializing in advanced molecular diagnostic testing platforms that deliver lab-quality results without requiring specialized laboratory infrastructure. Founded in 2011 and based in Goleta, California, the company's flagship Metrix platform enables rapid, accurate infectious disease diagnostics in multiple settings including urgent care centers, physician offices, hospitals, pharmacies, and homes. The FDA-authorized Metrix COVID-19 test provides rapid detection of COVID-19 and flu viruses using saliva or swab samples. The company is expanding its molecular testing portfolio to cover respiratory health, sexual health, and other infectious disease conditions. Aptitude's mission centers on democratizing diagnostics by making molecular-level testing accessible, affordable, and operationally simple for healthcare providers and patients globally, while addressing cost and usability challenges inherent in traditional laboratory-based diagnostics.

Intramedical Imaging LLC manufactures and markets molecular imaging instruments for intraoperative cancer detection. The company has specialized in gamma probe technology since 1998, developing radioguided surgery solutions for sentinel lymph node mapping, radioactive seed localization, radioguided parathyroidectomy, and tumor localization. Their flagship product, the Node Seeker 2000 Gamma Probe, features the highest published sensitivity and resolution in the market—reportedly twice that of competing devices like the Neoprobe. The system includes a user-friendly touchscreen tablet control unit with real-time count display and battery monitoring. All probes are certified for Hydrogen Peroxide (H2O2) sterilization by Sterrad and Sterris, meeting OR infection control requirements. The Node Seeker system is designed for breast cancer, melanoma, and parathyroid surgery applications. The company serves surgical oncologists and OR staff in hospital and surgical center environments. Products are intraoperative molecular imaging devices for use during cancer surgery and endocrine procedures.

LumiQuick Diagnostics Inc. is a minority-owned, privately-held manufacturer of high-quality point-of-care testing and immunoassay kits for the global in vitro diagnostics market. Founded in 2006 and based in Santa Clara, California, the company develops rapid diagnostic tests in multiple formats including test cups, cards, dip tests, and multi-panels. Product lines span infectious disease detection (Dengue, Zika, Chikungunya, COVID-19), drugs of abuse screening, disease markers for cardiac and cancer indicators, fertility hormones, vitamin D assessment, oxidative stress measurement, veterinary diagnostics, food safety testing, and biological threat agent identification. LumiQuick's QuickProfile™ branded assays leverage immunochromatographic technology for qualitative and quantitative detection. The company also manufactures ELISA-based platforms and offers the FDA EUA-cleared Boson Rapid SARS-CoV-2 Antigen Home Test. Products are sold in bulk through local and international distributors, targeting clinical laboratories, point-of-care settings, and compliance screening applications.

Vivid Vision Inc develops digital vision care solutions for diagnosis and therapeutic training of binocular vision disorders and visual field assessment. The company manufactures two core platforms: Vivid Vision (VV), an advanced vision training system for amblyopia, strabismus, and convergence insufficiency delivered via VR-based home training; and Vivid Vision Perimetry (VVP), a precision at-home microperimetry system for clinical visual field testing in retinal and glaucoma disorders. VVP is validated for use as a functional vision endpoint in clinical trials for geographic atrophy, age-related macular degeneration, and glaucoma therapeutics. The company also offers EYEBAB VT, a therapeutic exercise platform with dozens of vision activities for clinic-based intervention. With over 100,000 patients in 50+ countries since 2014, Vivid Vision systems are used by major ophthalmic pharmaceutical companies and leading research institutions. Published studies demonstrate VVP achieves 6.8× better precision than standard automated perimetry, 2× better fixation stability, and 99% adherence to at-home testing protocols. The platform has been evaluated by premier institutions including the Retina Foundation of the Southwest and Duke University Medical Center. Vivid Vision Perimetry is clinically validated and industry-ready for phase I and II ophthalmology trials.

ImpediMed is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices for noninvasive clinical assessment and monitoring of fluid status and tissue composition. The company's flagship SOZO® Digital Health Platform is FDA-cleared and enables real-time measurement of body composition, fluid volumes, and tissue changes across multiple clinical applications. Primary use cases include early detection and monitoring of secondary lymphedema in cancer survivors, heart failure fluid management, medical weight management assessment, and wellness/longevity monitoring. The SOZO platform utilizes advanced BIS technology measuring 256 frequencies to separate intra- and extracellular fluid and deliver actionable insights at point of care. The company operates a cloud-connected SaaS model supporting personalized care monitoring across the patient treatment continuum, with global distribution in US, Europe, Australia, and other markets.

Pulmonx Corporation is a global medical technology company headquartered in Redwood City, California, with operations in Neuchâtel, Switzerland, founded in 1995. The company specializes in minimally invasive bronchoscopic interventions for severe emphysema and chronic obstructive pulmonary disease (COPD). Pulmonx pioneered bronchoscopic lung volume reduction (BLVR) technology and has established itself as a leader in interventional pulmonology solutions for patients unsuitable for or unresponsive to surgical intervention. The company's flagship product portfolio includes the Zephyr® Endobronchial Valve, a clinically validated device that reduces lung hyperinflation by occluding diseased airways, demonstrating significant improvements in lung function (FEV1), exercise capacity, and quality of life across multiple randomized controlled trials. The Chartis® Pulmonary Assessment System provides collateral ventilation assessment to optimize patient selection and treatment planning. The LungTraX Platform delivers cloud-based quantitative CT analysis for personalized treatment planning. Pulmonx's devices are FDA-approved and supported by extensive clinical evidence across four major randomized controlled trials, with over 100 published clinical summaries. The company maintains a global network of treating physicians and assessment centers, with rigorous credentialing criteria including specialized training, hands-on competency, and outcomes monitoring.

Eyenuk is a global AI-driven digital health company specializing in autonomous eye screening technology for detection of diabetic retinopathy, age-related macular degeneration, and glaucoma. The company develops deep learning algorithms for retinal image analysis and has pioneered the EyeArt® AI Eye Screening System, the world's most extensively validated autonomous AI tool for diabetic retinopathy detection, tested on over half a million patient visits and 2 million images in real-world clinical settings. EyeArt requires no expert human grading, dilation, or specialist interpretation—enabling complete imaging, grading, and reporting within a single office visit in under 60 seconds. The system integrates a fundus camera with proprietary deep learning and image quality assessment algorithms that robustly detect disease presence and extent per internationally recognized clinical scales. EyeArt holds FDA 510(k) clearance for autonomous diabetic retinopathy detection across multiple camera platforms, EU CE marking (Class IIb MDR certification), and Health Canada licensure. Recent validation studies demonstrate 91.3% sensitivity and 91.1% specificity for referable DR, and 98.5% sensitivity for vision-threatening DR, across 100,000+ consecutive patient encounters. The platform empowers primary care physicians, endocrinologists, nurses, and technicians to perform point-of-care screening without subspecialty training, addressing the critical gap in annual diabetic retinopathy screening compliance. Eyenuk collaborates with major research institutions, health systems (including NHS deployment), and safety-net providers. Additional products under development include EyeMark™ (progression tracking), EyeArt™ AMD, EyeArt™ Glaucoma, and EyeRead™ UWF (ultra-widefield lesion analysis).

Coreline Soft Co., Ltd. is a South Korean medical AI software developer specializing in diagnostic imaging analysis and clinical decision support. The company develops the AVIEW platform, a suite of AI-powered software solutions for detecting and analyzing pulmonary and neurological conditions from CT and other medical imaging modalities. Core product lines include AVIEW LCS Plus (lung nodule, emphysema, and coronary artery calcification detection), AVIEW LCS (lung nodule detection and characterization), AVIEW COPD (chronic obstructive pulmonary disease analysis), AVIEW CAC (coronary artery calcification scoring), AVIEW Lung Texture (pulmonary pattern analysis), AVIEW NeuroCAD (intracranial hemorrhage detection and diagnosis support), AVIEW ILA (interstitial lung abnormality analysis), AVIEW Modeler (3D medical image modeling and 3D printing), AVIEW RT ACS (organ auto-segmentation), and data management solutions including pseudonymization servers. The company serves healthcare facilities globally, with established partnerships in Europe, North America, and Asia-Pacific for lung cancer screening programs and clinical research. Solutions integrate with existing hospital PACS and clinical workflows to automate image interpretation and provide radiologists with quantitative diagnostic support. The company publishes peer-reviewed clinical research demonstrating product utility and has exceeded 500 clinical publications. Regulatory approvals and certifications are indicated by deployment in hospitals across multiple jurisdictions, though specific FDA 510(k) or CE mark designations are not explicitly stated in available content.

Silver Lake Research Corporation develops, manufactures, and markets rapid point-of-care diagnostic test kits with proprietary EAP™-derived monoclonal antibodies. Founded in 1992, the company specializes in lateral flow immunoassays that deliver laboratory-grade accuracy and sensitivity in minutes at the point of care. The company operates an ISO 13485-compliant, FDA-registered US manufacturing facility—one of the largest independent automated production lines for lateral flow tests—enabling high-volume production of both proprietary products and contract-manufactured diagnostics. Key product lines include HemoTypeSC (hemoglobin phenotyping for sickle cell disease screening), WaterSafe (drinking water quality testing), and RapidBac (rapid urinary tract infection detection requiring no instrumentation). The company has marketed 150+ products and produced over 15 million test strips globally. Services include custom immunoassay development, bespoke assays for specific instruments, and private-label manufacturing. Silver Lake Research serves clinical laboratories, point-of-care testing environments, and contract manufacturing customers. The company emphasizes tangible innovation in antibody development and manufacturing partnerships, positioning itself as a turnkey solution provider for rapid diagnostic platforms.

Visby Medical manufactures FDA-authorized at-home PCR diagnostic test kits for sexually transmitted infections (STIs). The company's flagship product is the Visby Women's At-Home STI Test Kit, which detects chlamydia, gonorrhea, and trichomoniasis with lab-quality PCR accuracy in 30 minutes without clinic visits or mail-in delays. The device combines point-of-care molecular diagnostics technology with a smartphone app for result delivery, instruction videos, and privacy-protected result viewing. Visby's tests are delivered discreetly to patients' homes with clear step-by-step instructions designed for ease of use. The company integrates telemedicine support through third-party licensed providers who can prescribe same-day treatment for positive results. Visby is trusted by major health systems including Mayo Clinic, Optum, Cedars-Sinai, Dignity Health, Mass General Brigham, and Johns Hopkins University. The product has received FDA marketing authorization and represents a significant advancement in bringing gold-standard PCR diagnostics to the consumer market. Visby's focus is on removing barriers to sexual health testing by eliminating clinic wait times, reducing stigma through at-home testing, and enabling rapid treatment initiation.

Magnes AG is an ETH Zurich spinoff headquartered in Zurich, Switzerland, specializing in AI-powered gait analysis and mobility support through wearable smart footwear integrated with vibrotactile feedback technology. The company develops sensorized shoes that continuously monitor walking patterns, balance, and gait disruptions in real-world environments, delivering clinical-grade movement data outside traditional laboratory settings. Their core technology uses real-time haptic cues delivered through built-in vibration systems to help users—particularly those with neurological conditions affecting movement—reconnect with their feet and develop more confident walking patterns. Magnes offers three product tiers: NUSHU (medical-grade for healthcare professionals), NUSHU X (consumer wellness), and NUSHU Research (for academic institutions). The NUSHU system captures over 35 gait parameters and employs closed-loop AI algorithms that adapt vibration rhythms, intensities, and patterns to individual patient needs. Applications include support for Parkinson's disease, freezing of gait, mobility disorders, and general activity monitoring. The company has demonstrated clinical partnerships with leading institutions including UC San Diego, Harvard University, Stanford, University of Zurich, and Northumbria University. Since product launch in 2021, Magnes has analyzed millions of steps and maintains multiple ongoing clinical trials. The technology is designed for ease of use—shoes function as standard footwear with no wires or complicated setup—and operates continuously in daily living environments.

DiaSorin Molecular LLC is a world leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics. The company develops and manufactures in vitro diagnostic systems for detecting antibodies, antigens, and pathogens in biological specimens. Core product lines include the LIAISON® immunodiagnostic platform for infectious disease detection (tuberculosis, hepatitis, viral infections), Simplexa® molecular assay kits for direct pathogen detection (COVID-19, influenza, RSV, cytomegalovirus, herpes simplex virus), and the LIAISON NES® CLIA-waived rapid molecular test delivering results in approximately 15 minutes. Additional offerings include LIAISON® MeMed BV® for bacterial-viral differentiation, LIAISON® QuantiFERON®-TB Gold Plus II for TB detection, and LIAISON® BRAHMS PCT® for infection triage. The company also operates the Luminex division, providing xMAP® multiplex assay platforms and xMAP INTELLIFLEX® systems for research and clinical diagnostics, along with custom assay design and development services. DiaSorin serves clinical laboratories, hospitals, and research institutions globally. The company maintains regulatory compliance with FDA clearances and CLIA waivers for its diagnostic systems. Manufacturing and service capabilities span immunoassay automation, molecular PCR testing, and multiplex diagnostic platforms.

Lumos Diagnostics is an ASX-listed developer, manufacturer, and distributor of point-of-care diagnostic technologies that deliver rapid, cost-effective diagnostic test solutions for healthcare professionals. The company specializes in rapid blood-based diagnostic assays and proprietary digital reader platforms that enable real-time assessment and differentiation of medical conditions at the point-of-care. FebriDx® is their flagship product—a rapid fingerstick blood test that aids differentiation between bacterial and non-bacterial infections, supporting clinical decision-making around antibiotic use. The company also offers ViraDx and reader platforms. Beyond proprietary products, Lumos provides comprehensive contract development and manufacturing services including strategic innovation and assay development, product development and manufacturing transfer using Lumos technology platforms, clinical and product validation, and commercial-scale manufacture of test strips and digital readers. Their in-house qualified team supports all stages from concept through commercialization, including medical, quality, and regulatory affairs. The US headquarters is located in Carlsbad, California, with a corporate office in Melbourne, Australia. Lumos serves global markets through qualified clinicians, healthcare systems, and diagnostic product manufacturers seeking custom point-of-care diagnostic solutions.

Glycominds Diagnostics is a clinical laboratory diagnostics company specializing in non-invasive biomarker-based solutions for gastrointestinal diseases. The company develops and offers blood-based diagnostic tests for detection, prognosis, and monitoring of inflammatory bowel diseases (IBD), including Crohn's disease and Celiac disease. Product portfolio includes biomarkers for IBD diagnosis, Crohn's disease prognosis assessment, and monitoring of mucosal healing and anti-TNF therapy response. Glycominds positions its offerings as cost-effective alternatives to invasive diagnostic techniques such as endoscopy, providing gastroenterologists and primary care providers with accurate, non-invasive options for patient stratification and treatment monitoring. The company serves healthcare providers managing patients with gastrointestinal inflammatory conditions across multiple care settings.

Axxin is a diagnostic instrumentation company specializing in molecular and lateral flow diagnostic platforms for point-of-care, laboratory, and field-deployed testing. Founded over 18 years ago, the company develops and manufactures portable diagnostic instruments that enable rapid testing without centralized laboratory infrastructure. Core product lines include lateral flow array systems (e.g., AX-2X-S-E Array) and molecular diagnostics instruments (e.g., T8-ISO, T8-ISO-RA) for pathogen detection, contamination monitoring, and rapid clinical decision-making. Axxin offers both off-the-shelf standard products and custom development services with full regulatory support. The company provides expertise in instrument design, industrial design, and sensor technologies, supporting diagnostic innovators through product development cycles and regulatory pathways. Applications span infectious disease diagnosis, water/soil contamination assessment, and point-of-care clinical testing. ISO 13485 certified for medical device quality management. Serves global markets including clinical laboratories, field deployment sites, and point-of-care settings across healthcare, environmental monitoring, and food safety sectors.

O.N. Diagnostics develops non-invasive diagnostic applications for bone health and fracture risk assessment. The company's FDA-cleared VirtuOst® technology performs Biomechanical Computed Tomography (BCT) analysis, providing comprehensive measurements of bone mineral density and bone strength using existing CT scans of the hip or spine without requiring additional radiation, special imaging protocols, or calibration phantoms. VirtuOst identifies patients with osteoporosis and high-risk osteopenia, supporting clinical decision-making in patient care while enabling research applications in clinical trials, drug development, and medical device design. Since 2005, the company has maintained leadership in clinical bone assessment research and collaborates with academic and industry partners internationally.

Qvin develops non-invasive diagnostic solutions leveraging menstrual blood biomarkers for women's health screening and disease monitoring. The company's flagship product, the Q-Pad, is an FDA-cleared diagnostic menstrual pad that passively collects menstrual blood via an embedded Dried Menstrual Sample strip, enabling at-home collection of clinically valuable biospecimens without needles or invasive procedures. The Q-Pad has demonstrated strong clinical correlation with venous blood samples for biomarkers including HbA1c (r=0.96), TSH, and AMH (r>0.9), supporting its use in detecting and monitoring multiple conditions including diabetes, cervical cancer (HPV detection), endometriosis, sexually transmitted infections, and uterine fibroids. Qvin's research indicates menstrual effluent contains endometrial cells, immune components, hormones, and protein biomarkers reflective of both gynecological and systemic health, positioning it as an alternative to invasive biopsies, needle-based blood collection, and speculum-driven examinations such as Pap smears. The company partners with diagnostic platforms, healthcare organizations, and research institutions to expand the clinical validation and deployment of menstrual blood-based diagnostics. Qvin targets the women's health market, particularly addressing diagnostic access gaps in underserved populations. The company maintains an active research collaboration program with scientists, foundations, and non-profits to support clinical validation studies and innovation in period-blood diagnostics.

Qualigen, Inc. manufactures the FastPack® immunoassay analyzer platform, a point-of-care and laboratory diagnostic system designed for rapid, accurate immunoassay testing in hospitals, clinics, and doctor's offices. The FastPack technology platform specializes in quantitative human chorionic gonadotropin (hCG) testing for women's health diagnostics, with expanding applications in immunoassay testing. The company positions its solutions as quick, simple, and accurate alternatives to traditional laboratory workflows, emphasizing time savings, cost reduction, and improved patient outcomes. Qualigen distributes its analyzers and consumable test kits through group purchasing organization (GPO) partnerships, including recent expansion via Afaxys GPO agreements. The company provides comprehensive customer support including technical assistance, supply ordering, training resources, and safety documentation (SDS). While specific regulatory certifications are not detailed on the primary website content provided, the company operates in the clinical diagnostics space serving hospital and clinic laboratory settings. Manufacturing and service capabilities appear centralized at the Carlsbad, California headquarters location.

Mundy Medical Marketing is a medical device and surgical supplies distributor founded in 1979, specializing in sports medicine, arthroscopic, and general surgical products. The company is classified as a NAISC 423450 distributor and serves inpatient and outpatient surgical markets. Their primary offering is Fluoro-Shield Radiation Reduction Gloves, a sterile surgical glove product engineered with dense protective material that provides superior radiation attenuation compared to lead-loaded alternatives. Testing demonstrates 57% radiation reduction at 60 KVP and 33% at 120 KVP, significantly outperforming standard lead-loaded gloves. The gloves are manufactured from soft natural latex rubber with inherent surgical glove properties, packaged sterile in boxes of three, and available in sizes 7–9. The company holds U.S. Patents 5001354 and 5215701 for this technology. Mundy Medical serves physicians and surgical teams requiring hand protection during fluoroscopy-guided procedures where standard radiation badges do not accurately reflect exposure levels. The company emphasizes high-quality products at competitive pricing with dedicated sales and customer service support.

Active Life Scientific is the industry leader in tactile assessment of tissue, specializing in bone quality measurement. The company pioneered Reference Point Indentation (RPI) technology, enabling quantified-touch for surgeons and physicians. BoneScore® is the first FDA-cleared (De Novo) device for non-invasive, radiation-free tactile assessment of bone biomechanical properties, measuring bone strength and fracture toughness at critical fracture sites (hip, wrist, spine). The OsteoProbe® delivers real-time tactile feedback and in vivo/in situ material measurement, complementing traditional bone density tests like DXA. Applications span orthopedic surgery, osteoporosis assessment, fracture risk evaluation, arthroplasty planning, and bone health monitoring. Technology applicable to preclinical research, biomaterials characterization, and tissue engineering.

Shanghai Sun Biotech Co., Ltd. is a global supplier of thrombosis and hemostasis diagnostic solutions. Founded in 2001, the company specializes in the research, development, production, and distribution of coagulation analyzers, diagnostic reagents, and medical consumables for hemostasis and thrombosis testing. The company operates four primary product lines: UR Series (coagulation analyzers), UL Series (lab automation systems), UG Series (compact coagulation analyzers), and UP Series (portable coagulation analyzers). Product portfolio includes over 120 coagulation products and reagents compatible with multiple leading analyzer platforms (SUNBIO, SYSMEX, Werfen, and Stago instruments). Medical consumables span collection tubes, reagent cups, and related supplies. The company serves a global customer base of over 10,000 clients and operates manufacturing facilities exceeding 40,000 square meters. SunBio holds CE product certifications and conducts multi-center clinical studies for coagulation factor assays and hemostasis markers. The company focuses on thrombosis prevention, coagulation monitoring, and hemostasis assessment across clinical laboratory and hospital settings.

Diagnostics for the Real World (DRW) develops decentralized point-of-care (POC) molecular diagnostic systems for use in clinical and non-laboratory settings. The company's flagship platform, SAMBA, is a molecular diagnostic machine designed to deliver rapid pathogen detection at the site where patients are seen, enabling prompt clinical intervention. DRW's SAMBA platform performs multiplex molecular testing for respiratory pathogens including COVID-19, Influenza A/B, and RSV. The system is engineered for simplicity and high performance, supporting "one sample, one test" workflows in hospitals, laboratories, and non-laboratory environments. The company has received regulatory approval in multiple markets, including New Zealand, and maintains a distributed network of service partners and distributors globally. DRW emphasizes decentralized testing infrastructure and rapid turnaround diagnostics as core capabilities. The SAMBA II represents a breakthrough in POC molecular diagnostics and has achieved recognition in major institutional collections and exhibitions. The company provides service and training support, maintains open-access testing programs, and publishes clinical evidence. Manufacturing and regulatory credentials are consistent with EU and international diagnostic standards.

SUDOSCAN Inc. manufactures and distributes the SUDOSCAN device, a Class IIa medical device for early detection and monitoring of peripheral autonomic neuropathies and small fiber neuropathy. The device uses electrochemical skin conductance (ESC) measurement via electrode stimulation of sweat glands to assess sudomotor function and autonomic nerve fiber integrity. A non-invasive test completed in under 3 minutes with no patient preparation required, SUDOSCAN is indicated for diabetic neuropathy screening, chemotherapy-induced peripheral neuropathy (CIPN) monitoring, and evaluation of neuropathies associated with amyloidosis, Sjögren's syndrome, Fabry disease, Hepatitis C, and other neurological conditions. The device consists of a computer system with four electrodes where patients place hands and feet; results are automatically displayed as electrochemical skin conductance scores indicating presence and severity of autonomic dysfunction. Manufactured by parent company Impeto Medical SAS (France headquarters), SUDOSCAN has sold over 5,000 devices worldwide and is included in clinical guidelines from the European Network for TTR-FAP Amyloidosis, German diabetes management guidelines, and Latin American diabetes associations. CE-marked and FDA-cleared for use. The company also offers SudoCloud, a secure cloud-based remote patient monitoring platform for connecting, retrieving, and managing patient data. Clinical evidence includes 150+ peer-reviewed journal publications supporting reliability and diagnostic utility across multiple therapeutic areas.

Invetech is a design, engineering, and contract manufacturing partner specializing in diagnostic instruments and cell therapy automation solutions. With over 35 years of experience, the company serves life sciences, biotech, and healthcare organizations, offering end-to-end capabilities from concept through commercialization. Core competencies include instrument design and development, contract manufacturing, custom workflow automation for cell therapy applications, and production-scale manufacturing solutions. Invetech supports product development across benchtop and point-of-care (POC) systems through large core laboratory instruments and mid- to high-throughput platforms. The company maintains a library of interchangeable modular subsystems designed to reduce development risk and improve product reliability. Service offerings encompass custom process automation, formulation and fill systems, and configurable automation platforms. Invetech works with diagnostics companies and cell therapy developers to transition technologies from clinical workflows to commercial manufacturing. The company positions itself as an extension of client engineering teams, integrating specialists in engineering, science, design, and program management.

Immuno Concepts, NA Ltd. is a diagnostic assay manufacturer specializing in systemic rheumatic disease detection, founded in 1979. The company pioneered the conversion from rodent tissue to HEp-2 cells for anti-nuclear antibody (ANA) detection and developed HEp-2000®, a patented ANA substrate with enhanced sensitivity for autoantibodies to SS-A/Ro and other connective tissue disease markers. Product lines include indirect fluorescent antibody (IFA) assays, enzyme immunoassay (EIA/ELISA) systems branded as RELISA™, ColorZyme™ chemiluminescent substrates, and automated specimen processing platforms. The company recently achieved FDA clearance for its IgG Anti-nDNA Fluorescent Test System for use with the Image Navigator® automated imaging platform. Immuno Concepts serves clinical laboratories and rheumatology practices with diagnostic reagents and systems for autoimmune disease detection. The company manufactures and distributes diagnostic reagents meeting FDA and international regulatory standards for in vitro diagnostic use.